This site is intended for health professionals only

Published on 6 July 2007

Share this story:

Rosuvastatin freed from black triangle


Following a comprehensive analysis of pre- and postmarketing data by the UK’s MHRA and Commission on Human Medicines, the risk-benefit profile for rosuvastatin (Crestor

Most read

Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine